Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 1.6% Higher – Still a Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) traded up 1.6% during trading on Wednesday . The company traded as high as $6.62 and last traded at $6.54. 1,044,577 shares changed hands during trading, a decline of 82% from the average session volume of 5,804,447 shares. The stock had previously closed at $6.44.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on RXRX. Leerink Partners lowered their price objective on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a research note on Tuesday, September 3rd. KeyCorp lowered their price objective on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. Jefferies Financial Group lowered their price objective on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research note on Tuesday, September 3rd. Finally, Needham & Company LLC decreased their price target on Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating on the stock in a research report on Wednesday, September 4th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $9.40.

Recursion Pharmaceuticals Stock Performance

The company has a quick ratio of 6.07, a current ratio of 6.07 and a debt-to-equity ratio of 0.04. The company has a market cap of $1.51 billion, a P/E ratio of -4.04 and a beta of 0.80. The business has a fifty day moving average of $6.76 and a 200 day moving average of $7.96.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Thursday, August 8th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). The business had revenue of $14.42 million for the quarter, compared to the consensus estimate of $11.96 million. Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. Recursion Pharmaceuticals’s revenue was up 30.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.38) EPS. On average, equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.58 EPS for the current year.

Insiders Place Their Bets

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of the stock in a transaction on Tuesday, July 23rd. The stock was sold at an average price of $8.48, for a total value of $97,070.56. Following the completion of the transaction, the director now owns 7,155,663 shares in the company, valued at approximately $60,680,022.24. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Blake Borgeson sold 11,447 shares of the stock in a transaction on Tuesday, July 23rd. The stock was sold at an average price of $8.48, for a total transaction of $97,070.56. Following the sale, the director now directly owns 7,155,663 shares of the company’s stock, valued at $60,680,022.24. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Christopher Gibson sold 20,000 shares of the stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $6.16, for a total value of $123,200.00. Following the sale, the chief executive officer now directly owns 762,656 shares in the company, valued at $4,697,960.96. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 186,682 shares of company stock worth $1,258,852. 15.75% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Mubadala Investment Co PJSC bought a new stake in Recursion Pharmaceuticals during the 4th quarter valued at approximately $128,041,000. ARK Investment Management LLC grew its holdings in Recursion Pharmaceuticals by 14.5% during the 2nd quarter. ARK Investment Management LLC now owns 28,142,918 shares of the company’s stock valued at $211,072,000 after buying an additional 3,555,357 shares in the last quarter. Baillie Gifford & Co. grew its holdings in Recursion Pharmaceuticals by 10.5% during the 2nd quarter. Baillie Gifford & Co. now owns 26,589,936 shares of the company’s stock valued at $199,425,000 after buying an additional 2,522,132 shares in the last quarter. Kinnevik AB publ increased its position in shares of Recursion Pharmaceuticals by 14.4% during the 2nd quarter. Kinnevik AB publ now owns 11,905,668 shares of the company’s stock valued at $89,293,000 after purchasing an additional 1,500,000 shares during the last quarter. Finally, Lingotto Investment Management LLP increased its position in shares of Recursion Pharmaceuticals by 69.0% during the 2nd quarter. Lingotto Investment Management LLP now owns 3,675,077 shares of the company’s stock valued at $27,563,000 after purchasing an additional 1,500,000 shares during the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.